...
首页> 外文期刊>Drug delivery. >The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery
【24h】

The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery

机译:壳聚糖-6-巯基烟酸纳米颗粒在口服肽药物递送中的应用

获取原文
           

摘要

The aim of this study was to develop a novel nanoparticulate formulation and test its potential for oral peptide drug delivery. Chitosan-6-mercaptonicotinic acid is a novel thiolated chitosan with strong mucoadhesive properties. Nanoparticles were developed by an ionic gellation method. The obtained particles were characterized in terms of mucoadhesion, stability, toxicity, and in vitro release. Human insulin (HI) was chosen as a model peptide drug, incorporated in the particles and orally administered to rats. Human insulin was quantified in the blood by means of ELISA. The size of the obtained particles was in the range of 200–300?nm and the zeta potential was determined to be +8?+23 depending on the amount of thiol groups attached on the polymer. After 3?h of incubation up to 60% of the thiolated chitosan nanoparticles remained attached to the mucosa in contrast to 20% of unmodified chitosan particles. The AUC of HI after oral administration of thiolated chitosan nanoparticles was 4-fold improved compared to unmodified chitosan nanoparticles. Due to these improvements, chitosan-6-mercaptonicotinic acid nanoparticles are promising vehicles for oral delivery of peptide drugs.
机译:这项研究的目的是开发一种新型的纳米颗粒制剂,并测试其口服肽药物递送的潜力。壳聚糖-6-巯基烟酸是一种新型的硫醇化壳聚糖,具有很强的粘膜粘附特性​​。纳米颗粒通过离子凝胶化方法开发。根据粘膜粘附性,稳定性,毒性和体外释放来表征获得的颗粒。选择人胰岛素(HI)作为模型肽药物,将其掺入颗粒中并口服给予大鼠。通过ELISA定量血液中的人胰岛素。所获得的颗粒尺寸在200-300?nm范围内,取决于聚合物上所连接的硫醇基团的量,ζ电位被确定为+8?+23。温育3小时后,与未修饰的壳聚糖颗粒的20%相比,多达60%的硫醇化壳聚糖纳米颗粒仍然附着在粘膜上。与未修饰的壳聚糖纳米颗粒相比,口服硫醇化壳聚糖纳米颗粒后HI的AUC提高了4倍。由于这些改进,壳聚糖-6-巯基烟酸纳米颗粒是用于口服给药肽药物的有前途的载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号